辛伐他汀联合非诺贝特对混合型高脂血症的临床疗效及血清TC、LDL-C、TG、HDL-C水平的影响  

Clinical efficacy of simvastatin and fenofibrate in treatment of mixed hyperlipidemia and their influence on serum TC,LDL-C,TG and HDL-Clevels

作　　者：岳枫[1] 王文生[1] 张培勇[2] 傅颖[3] 

机构地区：[1]河南省鹤壁职业技术学院护理学院,河南鹤壁313000 [2]河南省卫辉市新乡医学院第一附属医院心血管内一科,河南卫辉453100 [3]浙江省医学科学院药学系,浙江杭州310007

出　　处：《中国生化药物杂志》2014年第3期119-121,共3页Chinese Journal of Biochemical Pharmaceutics

基　　金：浙江省医药卫生平台骨干人才计划(2011RCA002)

摘　　要：目的探讨辛伐他汀联合非诺贝特对混合型高脂血症患者的临床疗效及血清TC、LDL-C、TG、HDL-C水平的影响。方法将168例混合型高脂血症患者随机分为3组,辛伐他汀组(辛伐他汀10 mg/d,n=54)、非诺贝特组(非诺贝特200 mg/d,n=55)及联合治疗组(非诺贝特200 mg/d+辛伐他汀10 mg/d,n=57),均治疗5个月,监测各组主要血脂参数TC、LDL-C、TG、HDL-C水平的变化,同时观察药物的不良反应。结果治疗5个月后,与治疗前相比,3组治疗指标参数均有所改善,联合治疗组改善效果最为明显,TC、LDL-C及TG分别下降33%、37%及55%,HDL-C上升25%;联合治疗组的TC、LDL-C及TG降幅显著大于辛伐他汀组与非诺贝特组(P<0.05),HDL-C的升幅也显著高于其他2组;联合治疗组的TC、LDL-C及TG的全部达标率为46%,明显高于另外2组,差异均有统计学意义(P<0.05);3组不良反应发生较少,差异无统计学意义。结论联合应用辛伐他汀与非诺贝特对混合型高脂血症患者的疗效要优于单独使用辛伐他汀或非诺贝特,且具有良好的安全性。Objective To explore the clinical efficacy of simvastatin and fenofibrate in treatment of mixed hyperlipidemia and their influence on serum TC,LDL-C,TG and HDL-C levels.Methods 168 cases with mixed hyperlipidemia were randomly divided into three groups,simvastatin group (simvastatin 10 mg/d,n=54),fenofibrate group(fenofibrate 200 mg/d,n=55)and combined treatment group(fenofibrate 200 mg/d+simvastatin 10 mg/d,n=57),all patients were treated for 5 months.The change of lipid parameters such as TC,LDL-C,TG and HDL-C levels were monitored and adverse drug reaction were observed. Results After 5 months treatment,compared with before,the indexes in three groups were all improved,and the combined treatment group was most obvious,TC,LDL-C and TG levels in it were decreased by 33%,37% and 55%,HDL-C rose by 25%.The decreased degree of TC,LDL-C and TG in combined treatment group were more than simvastatin and fenofibrate group(P<0.05 ),while HDL-C was higher than the other two groups(P<0.05).The total achieved rate of TC,LDL-C and TG in combined treatment group was 46%,significantly higher than the other two groups(P<0.05).Adverse reactions in three groups were all few,and there was no significant difference.Conclusion The efficacy of simvastatin and fenofibrate in treatment of patients with mixed hyperlipemia is better than simvastatin and fenofibrate use alone,and it is safe.

关 键 词：混合型高脂血症 辛伐他汀 非诺贝特 

分 类 号：R589.2[医药卫生—内分泌]